Research progress on immunotherapy for peritoneal mesothelioma

VernacularTitle:免疫治疗在腹膜间皮瘤中的研究进展
Author: Zhang JIAXIN ¹ ; Lu LITING ¹ ; Ba YI ¹ ; Wang XICHENG ¹
Author Information

1. 中国医学科学院北京协和医院肿瘤医学中心(北京市 100032)
Publication Type:Journal Article
Keywords: immunotherapy; peritoneal mesothelioma(PeM); immune checkpoint inhibitors(ICIs); combination therapy
From: Chinese Journal of Clinical Oncology 2025;52(1):40-46
CountryChina
Language:Chinese
Abstract: Peritoneal mesothelioma(PeM),which originates in cells in the visceral and mural layers of the peritoneum,is a rare and highly aggressive malignant tumor that accounts for approximately 15%of all mesotheliomas.The disease is characterized by insidious onset and poor prognosis,and its mechanisms of tumorigenesis and progression have not been fully elucidated.Asbestos exposure is a major risk factor for mesothelioma.Effective treatment options alternative to cytoreductive surgery(CRS),hyperthermic intraperitoneal chemotherapy(HIPEC),and platinum/pemetrexed(conventional treatments)are currently lacking.Immunotherapy,which mobilizes the immune system,has shown initial efficacy in patients with advanced mesotheliomas.However,additional real-world clinical trials and studies on immuno-therapeutic targets remain needed.This article reviews progress in PeM-related immunotherapy clinical studies and potential targets in PeM treatment.